title: Vascular prostheses with controlled release of antibiotics Part 2. In vitro biological evaluation of vascular prostheses treated by cyclodextrins.
abstract: Viability tests by the colony forming method show no toxicity for all CDs (beta-CD, gamma-CD, HPbeta-CD and HPgamma-CD) and their associated polymer. A survival rate of 100% is observed for all CDs at high concentration 400 ppm. Proliferation tests revealed a low proliferation of L132 cells on grafted vascular prostheses and untreated prostheses and good proliferation on Melinex (film form of PET). A proliferation of 17% is observed after 3 days of incubation and decrease at 4% after 6 days on prostheses. Melinex exhibits a proliferation rate as the controls. Vitality tests confirm proliferation tests and show a good vitality of cells even for low cell amounts. From these experiments it becomes obvious that the decreasing proliferation rate is not a cytotoxic effect but is due to the chemical and/or physical surface characteristics. A similar result is obtained for cell adhesion kinetics between grafted vascular prostheses and control. After 2 h adhesion, a lower adhesion is observed on untreated prostheses. Theses results were confirmed by immunochemistry and morphology tests. This cell adhesion inhibiting effect of the PET prostheses contributes to a better "survival" of vascular prostheses without secondary obstruction or stenosis.
authors.affiliation: Groupe de Recherche sur les Biomatériaux, EA 1049, Faculté de Médecine, 59045 Lille, France.
authors.forename: N
authors.initials: N
authors.lastname: Blanchemain
authors.forename: S
authors.initials: S
authors.lastname: Haulon
authors.forename: F
authors.initials: F
authors.lastname: Boschin
authors.forename: M
authors.initials: M
authors.lastname: Traisnel
authors.forename: M
authors.initials: M
authors.lastname: Morcellet
authors.forename: B
authors.initials: B
authors.lastname: Martel
authors.forename: H F
authors.initials: HF
authors.lastname: Hildebrand
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000737:chemistry; D001807:Blood Vessel Prosthesis / Q000009:adverse effects*; D020099:Coated Materials, Biocompatible / Q000009:adverse effects* / Q000737:chemistry; D003505:Cyclodextrins / Q000008:administration & dosage* / Q000737:chemistry; D003692:Delayed-Action Preparations / Q000008:administration & dosage* / Q000737:chemistry; D019544:Equipment Failure Analysis; D008422:Materials Testing; D011092:Polyethylene Glycols / Q000737:chemistry*; D011093:Polyethylene Terephthalates; D011475:Prosthesis Failure; D016459:Prosthesis-Related Infections / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000900:Anti-Bacterial Agents; D020099:Coated Materials, Biocompatible; D003505:Cyclodextrins; D003692:Delayed-Action Preparations; D011093:Polyethylene Terephthalates; D011092:Polyethylene Glycols